PI
BMY.RT

PEAK6 Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

PEAK6 Investments’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,160
Closed -$6K – 5890
2020
Q4 		$6K Hold
8,160
– – ﹤0.01% 4439
2020
Q3 		$18K Hold
8,160
– – ﹤0.01% 4142
2020
Q2 		$29K Sell
8,160
-93,700
-92% -$338K ﹤0.01% 4124
2020
Q1 		$5.68M Buy
101,860
+91,200
+856% +$300K 0.03% 491
2019
Q4 		$32K Buy
+10,660
New +$27.7K ﹤0.01% 3111

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

PEAK6 Investments's BMY.RT Position: Q1 2021 in Review

PEAK6 Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 8,160 shares — an estimated $6K sold.

PEAK6 Investments first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $5.68M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • PEAK6 Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • PEAK6 Investments sold 8,160 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $6K.
  • PEAK6 Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • PEAK6 Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $5.68M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on PEAK6 Investments's 13F filing for Q1 2021, filed 14 May 2021.